Under the patronage of the Saudi Crown Prince and Prime Minister, Mohammed bin Salman, Saudi Arabia will host the third edition of Riyadh Global Medical Biotechnology Summit (RGMBS 2024) from November 10-12, 2024 in Riyadh.
According to the Saudi Press Agency (SPA), the Ministry of National Guard Health Affairs organizes the event, in collaboration with the Ministry of Investment, as a strategic partner.
Fostering Biotechnology
The third edition of the RGMBS is a testament to Saudi leadership’s unwavering support for this vital sector, which contributes to achieving sustainable development and bolstering the national economy.
Furthermore, it aligns with the objectives of the National Biotechnology Strategy, which the Saudi Crown Prince launched in January 2024, outlining the Kingdom’s ambitious vision to develop advanced biotechnologies in the fields of medicine, agriculture, environment and industry.
The strategy aims to transform Saudi Arabia into a leading biotechnology regional hub across the Middle East and North Africa by 2030 and a global hub by 2040.
Biotechnology is a pivotal element and an essential enabler for achieving Vision 2030 key pillars of building a vibrant society and a sustainable and thriving economy which relies on technological research and development to enhance knowledge, innovation and science.
Global Participation in RGMBS 2024
In the light of this, the RGMBS 2024 will bring together international leaders and experts in the field of medical biotechnology.
Moreover, the summit will see the participation of companies from the US, the UK, China, South Korea, Japan and other countries that play a pioneering role in the industries of biotechnology, pharmaceuticals, and medical technologies.
Several prestigious organizations and academic institutions will also take part in the RGMBS 2024, adding to the significance of the event on the regional and global health map.
The previous edition of the RGMBS yielded in signing 11 cooperation agreements with international entities in the fields of medical research, vaccine production, and knowledge localization. It also featured 68 local and global speakers, and over 14,300 participants from 128 countries.